Skip to main content

COVID-19

      RT @KDAO2011: In case you missed it. @ACRheum #COVIDvaccine guidance v 4.0 for Rheum patients & what's added:
      👉3r
      3 years 5 months ago
      In case you missed it. @ACRheum #COVIDvaccine guidance v 4.0 for Rheum patients & what's added: 👉3rd dose recommend, timing relative to meds (as before) 👉mRNA booster preferred if initial doses were mRNA 👉mAb as PrEP/Rx for high risk pts https://t.co/R8K8WeZBMt
      RT @KDAO2011: Abst#0858 Hopkins SLE Cohort 860 pts, 65 w/COVID19, 228 vax'd:
      👉COVID19 infx did not increase dz activi
      3 years 5 months ago
      Abst#0858 Hopkins SLE Cohort 860 pts, 65 w/COVID19, 228 vax'd: 👉COVID19 infx did not increase dz activity, but aPLs were increased (rash decreased likely d/t quarantine and no sun exposure) 👉COVID19 vaccine did not affect dz activity #ACR21 @rheumnow https://t.co/C65qJuMIbk
      RT @drdavidliew: So fitting that @ACRheum President @DrDavidKarp has highlighted the amazing work of @rheum_covid in the
      3 years 5 months ago
      So fitting that @ACRheum President @DrDavidKarp has highlighted the amazing work of @rheum_covid in the #ACR21 Opening Session. In crazy times, it delivered results with unprecedented speed, when our patients needed it most. We will look back in history with thanks. @RheumNow https://t.co/cTnAZP9UDl
      RT @AkhilSoodMD: Abst 0501
      Kakkar & colleagues examined immunogenicity of single dose of SARS-CoV-2 Vaccine in patie
      3 years 5 months ago
      Abst 0501 Kakkar & colleagues examined immunogenicity of single dose of SARS-CoV-2 Vaccine in patients with systemic sclerosis - Vaccine is safe - Immunosuppression lowered Ab production but no effect on T cell response #ACR21 @RheumNow https://t.co/NsLrWHh7ZS
      RT @Nellziade: #LongCovid management #ACR21
      #CDC

      🔴Multidisciplinary approach: Holistic management
      🟢Arthralgias"
      3 years 5 months ago
      #LongCovid management #ACR21 #CDC 🔴Multidisciplinary approach: Holistic management 🟢Arthralgias" NSAIDs 🟢Brain fog: cognitive training 🟢 Anosmia/ dysgeusia: olfactory training 🟢 Fatigue: Exercise 🟢 Anxiety/ Depression/ PTSD: psychotherapy #ACRambassador https://t.co/dB1OHlO0bl
      RT @synovialjoints: Excellent session on COVID-19 update on therapeutics chaired by @rheum_cat Prof. Luis Ostrosky outli
      3 years 5 months ago
      Excellent session on COVID-19 update on therapeutics chaired by @rheum_cat Prof. Luis Ostrosky outlining the therapies at different phases of COVID-19 including antivirals, convalescent plasma, anticoagulation, exercise and long-term endemic phase @RheumNow #ACR21 Session6S424 https://t.co/jso7x1v1oA
      RT @swethaann23: Young et al. Impact of COVID-19 on rheumatology training
      302 rheumatology trainees from 33 countries su
      3 years 5 months ago
      Young et al. Impact of COVID-19 on rheumatology training 302 rheumatology trainees from 33 countries surveyed ➡️52% feel burned out🔼from prior ➡️66% felt supported by their program ➡️72% felt positive about being in Rheumatology Abst#0485 #ACR21 @RheumNow @kristenyoung
      RT @RichardPAConway: @kristenyoung @rheum_covid project on impact of COVID-19 on our trainees. Love the graphics by @EBR
      3 years 5 months ago
      @kristenyoung @rheum_covid project on impact of COVID-19 on our trainees. Love the graphics by @EBRheum . Negatives are physical health, stress levels, and burnout all ⬆️ . Positives? Trainees did feel supported by programmes. Abstr#0485 #ACR21 @RheumNow https://t.co/kXQ1AUNrgb
      RT @KDAO2011: My exclusive interview w/the GRA Powerhouse!
      What are they studying next?
      👉impact of COVID policies on
      3 years 5 months ago
      My exclusive interview w/the GRA Powerhouse! What are they studying next? 👉impact of COVID policies on Rheum pts 👉pt's perception w/COVID vaccines 👉COVID risk calculator 👉long haulers w/ rheum dz 👉breakthrough infections @rheumnow https://t.co/dVLayNchHT @rheum_covid https://t.co/B1KIjxYt15
      ×